Furthermore, results from GSE13159 implicated that the HOXA10 expression was higher in AML than that in other myeloid neoplasms (MDS/CML) and lymphoid malignancies (T-ALL/B-ALL), which indicated that HOXA10 overexpression may be AML-specific signature. Here, HOXA10 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.